QT time prolongation
Adverse drug events
Variants ✨For the computationally intensive evaluation of the variants, please choose the paid standard subscription.
Explanations of the substances for patients
We have no additional warnings for the combination of abarelix and selpercatinib. Please also consult the relevant specialist information.
The reported changes in exposure correspond to the changes in the plasma concentration-time curve [ AUC ]. We do not expect any change in exposure for abarelix, when combined with selpercatinib (100%). We do not expect any change in exposure for selpercatinib, when combined with abarelix (100%).
The pharmacokinetic parameters of the average population are used as the starting point for calculating the individual changes in exposure due to the interactions.
The bioavailability of abarelix is unknown. The terminal half-life [ t12 ] is rather long at 316.8 hours and constant plasma levels [ Css ] are only reached after more than 1267.2 hours. The protein binding [ Pb ] is 97.5% strong. The metabolism via cytochromes is currently still being worked on.
Selpercatinib has a mean oral bioavailability [ F ] of 73%, which is why the maximum plasma levels [Cmax] tend to change with an interaction. The terminal half-life [ t12 ] is rather long at 32 hours and constant plasma levels [ Css ] are only reached after more than 128 hours. The protein binding [ Pb ] is 97% strong. Since the substance has a low hepatic extraction rate of 0.06, displacement from protein binding [Pb] in the context of an interaction can lead to increased exposure. The metabolism mainly takes place via CYP3A4 and the active transport takes place partly via BCRP and PGP.
|Serotonergic Effects a||0||Ø||Ø|
Rating: According to our knowledge, neither abarelix nor selpercatinib increase serotonergic activity.
|Kiesel & Durán b||0||Ø||Ø|
Rating: According to our knowledge, neither abarelix nor selpercatinib increase anticholinergic activity.
QT time prolongation
Rating: In combination, abarelix and selpercatinib can potentially trigger ventricular arrhythmias of the torsades de pointes type.
General adverse effects
|Side effects||∑ frequency||aba||sel|
|Elevated serum creatinine||39.1 %||n.a.||39.1|
|Peripheral edema||38.7 %||n.a.||38.7|
Constipation (27.1%): selpercatinib
Diarrhea (23.5%): selpercatinib
Vomiting (16.2%): selpercatinib
Headache (24%): selpercatinib
Dizziness (14.6%): selpercatinib
Dyspnea (16%): selpercatinib
Fever (14.3%): selpercatinib
Elevated transaminases (9.8%): selpercatinib
Hemorrhage (2.4%): selpercatinib
Hypersensitivity reaction (1.6%): selpercatinib
Impaired wound healing: selpercatinib
Based on your answers and scientific information, we assess the individual risk of undesirable side effects. These recommendations are intended to advise professionals and are not a substitute for consultation with a doctor. In the restricted test version (alpha), the risk of all substances has not yet been conclusively assessed.
No literature information available.